H. Lundbeck starts clinical phase III study with Lu AA21004 in Japan
H. Lundbeck A/S and Takeda Pharmaceutical Company Limited announced the initiation of a phase III clinical trial in Japan for Lu AA21004 in patients with major depressive disorder (MDD).
This randomized, double-blind and multi-center phase III clinical trial is expected to enroll approximately 360 patients with MDD and will evaluate the efficacy and safety of Lu AA21004 (5 and 10 mg) compared to placebo. Primary endpoint is change of MADRS total score from baseline after eight weeks.
Lu AA21004 is a structurally novel compound that is different from currently available antidepressants. Data from clinical trials conducted outside Japan have shown encouraging results for the potential efficacy and the tolerability profile of Lu AA21004. In addition to the Japanese study, the ongoing clinical trial programme includes four ongoing short-term studies and two long-term safety studies.
Lundbeck and Takeda will continuously work in collaboration to develop Lu AA21004 in order to provide the drug as soon as possible as a novel treatment with patients suffering from depression.
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.